Last mentioned: Mar 24, 2026
Hybrid Submission Standards
Expected formalization of regulatory pathways that prioritize NAM data over animal data for specific drug classes.
FDA Warning Issued
The FDA flags the podcast statements as misleading and issues an Untitled Letter to ImmunityBio.
Podcast Appearance
Patrick Soon-Shiong discusses the drug's potential on a high-profile industry podcast.
OOC Commercialization
Widespread adoption of organ-on-a-chip systems in early-stage pharmaceutical R&D for toxicity screening.
Initial FDA Approval
Anktiva (N-803) receives FDA approval for BCG-unresponsive NMIBC.
EU Regulatory Shift
The European Parliament and EMA accelerate roadmaps for the phase-out of animal use in regulatory testing.
FDA Modernization Act 2.0
President Biden signs legislation removing the requirement for animal testing for biosimilars and new drugs.
The FDA has issued a formal warning to ImmunityBio and its founder, Patrick Soon-Shiong, regarding misleading public statements about the company's bladder cancer drug. The regulator cited claims made during a podcast that suggested broader efficacy than currently approved, raising concerns about off-label promotion.
The pharmaceutical industry is navigating a historic shift as the FDA Modernization Act 2.0 removes the mandate for animal testing in drug development. However, while technologies like organ-on-a-chip and AI offer higher human predictivity, they currently lack the systemic complexity required to fully replace animal models in late-stage safety assessments.